1. Home
  2. CNOB vs IOVA Comparison

CNOB vs IOVA Comparison

Compare CNOB & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConnectOne Bancorp Inc.

CNOB

ConnectOne Bancorp Inc.

HOLD

Current Price

$31.99

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$8.72

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNOB
IOVA
Founded
1982
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
CNOB
IOVA
Price
$31.99
$8.72
Analyst Decision
Buy
Buy
Analyst Count
4
10
Target Price
$31.25
$9.00
AVG Volume (30 Days)
275.9K
14.2M
Earning Date
04-23-2026
05-07-2026
Dividend Yield
2.48%
N/A
EPS Growth
N/A
14.84
EPS
1.51
N/A
Revenue
N/A
N/A
Revenue This Year
$42.85
$47.74
Revenue Next Year
$7.27
$40.31
P/E Ratio
$21.40
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.20
$1.76
52 Week High
$34.14
$9.36

Technical Indicators

Market Signals
Indicator
CNOB
IOVA
Relative Strength Index (RSI) 47.44 68.34
Support Level $31.52 $3.57
Resistance Level $33.95 $9.36
Average True Range (ATR) 0.57 0.56
MACD 0.00 -0.03
Stochastic Oscillator 59.95 70.51

Price Performance

Historical Comparison
CNOB
IOVA

About CNOB ConnectOne Bancorp Inc.

ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets, and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental, and consumer wages.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: